NEURALPLEXER
Live / Applied — First extension granted (statement of use) (as of 02 Apr 2026)
What this means for you
Not registered yet, but its 21 Jan 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99014025
- Mark type
- Stylized text
- Filed
- 21 Jan 2025
- Published for opposition
- 12 Aug 2025
- Attorney of record
- Alyssa M. Worsham
Goods and services
- Class 042 — Scientific and technological services: Drug discovery services; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence and machine learning for molecular docking; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for biomolecular structure prediction; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence in the field of drug design and development; research and development of new therapeutic targets for others; scientific and medical research; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for molecular docking; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for biomolecular structure prediction; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for automated machine learning in the field of drug design and development; advanced product research in the field of artificial intelligence (AI); research and development of pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; medical and scientific research services in the field of machine learning models for biomolecular structure prediction
Owner
- Iambic Therapeutics, Inc., San Diego, CA, US
- Iambic Therapeutics, Inc., San Diego, CA, US
Prosecution history
- 03 Apr 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Apr 2026 — SOU EXTENSION 1 GRANTED
- 02 Apr 2026 — SOU EXTENSION 1 FILED
- 02 Apr 2026 — SOU TEAS EXTENSION RECEIVED
- 07 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 12 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 12 Aug 2025 — PUBLISHED FOR OPPOSITION
- 06 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Jul 2025 — ASSIGNED TO EXAMINER
- 25 Jun 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 21 Jan 2025 — APPLICATION FILING RECEIPT MAILED
- 21 Jan 2025 — NEW APPLICATION ENTERED